Adam Feuerstein

Gilead's Encouraging Remdesivir Data: Rapid Reaction On The Stock

Gilead's Encouraging Remdesivir Data: Rapid Reaction On The Stock

BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial

BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial

Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study

Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study

BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial

BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial

Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study

Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study

What's Going On With Geron?

What's Going On With Geron?

Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed?

Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed?

What's Going On With Geron?

What's Going On With Geron?

Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed?

Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed?

Adam Feuerstein Cautious On Biogen Following Alzheimer's Study

Adam Feuerstein Cautious On Biogen Following Alzheimer's Study

Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

Adam Feuerstein Recent News

Alkermes Falls 20% After FDA Refusal To File Letter

Alkermes Falls 20% After FDA Refusal To File Letter

Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill

Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill

Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'

Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'

Novavax Shares Rise 30% On Positive Data, But Risks Remain

Novavax Shares Rise 30% On Positive Data, But Risks Remain

Pain Therapeutics Shares Double On Clinical Study Data

Pain Therapeutics Shares Double On Clinical Study Data

10 Financial Twitter Names To Follow In 2018

10 Financial Twitter Names To Follow In 2018

'Horrible': JPMorgan Chase Receives Pushback On Biotech Conference Restrictions

'Horrible': JPMorgan Chase Receives Pushback On Biotech Conference Restrictions

4 Biotechs Boosted By Spark Therapeutic's FDA News

4 Biotechs Boosted By Spark Therapeutic's FDA News

A Deep Dive Into MannKind's Big Bet On Afrezza

A Deep Dive Into MannKind's Big Bet On Afrezza

Selling The News In Acadia Pharmaceuticals

Selling The News In Acadia Pharmaceuticals

Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response

Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response

Zogenix's Dravet Syndrome Treatment Returns 'Strong'

Zogenix's Dravet Syndrome Treatment Returns 'Strong'

Anlayst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside

Anlayst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside

Street Puts Stamp Of Approval On Gilead's Kite Pharma Takeover

Street Puts Stamp Of Approval On Gilead's Kite Pharma Takeover

Puma Biotech Makes Big Breakthrough In Breast Cancer Treatment

Puma Biotech Makes Big Breakthrough In Breast Cancer Treatment

Will TherapeuticsMD's Yuvvexy Pass The FDA Muster?

Will TherapeuticsMD's Yuvvexy Pass The FDA Muster?

'Riding So More Jimmy's Can Ring The Bell': TheStreet's Adam Feuerstein To Bike For Jimmy Fund, Dana-Farber Cancer Institute

'Riding So More Jimmy's Can Ring The Bell': TheStreet's Adam Feuerstein To Bike For Jimmy Fund, Dana-Farber Cancer Institute

Neurotrope Denies Involvement In Paying For Promotional Articles

Neurotrope Denies Involvement In Paying For Promotional Articles

PreMarket Prep Recap For May 1: Feuerstein Breaks Down Neurotrop's Data Spin; Contrarianism Vs. Momentum Investing

PreMarket Prep Recap For May 1: Feuerstein Breaks Down Neurotrop's Data Spin; Contrarianism Vs. Momentum Investing

Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here'

Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here'

Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance

Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance

Exondys Sales, Takeover Speculation Fuel Sarepta Therapeutics

Exondys Sales, Takeover Speculation Fuel Sarepta Therapeutics

The Bull-Bear Debate In Therapeutics Rages From Research Notes To Twitter

The Bull-Bear Debate In Therapeutics Rages From Research Notes To Twitter